NO20063080L - Azepinoindolderivater som farmasoytiske midler - Google Patents

Azepinoindolderivater som farmasoytiske midler

Info

Publication number
NO20063080L
NO20063080L NO20063080A NO20063080A NO20063080L NO 20063080 L NO20063080 L NO 20063080L NO 20063080 A NO20063080 A NO 20063080A NO 20063080 A NO20063080 A NO 20063080A NO 20063080 L NO20063080 L NO 20063080L
Authority
NO
Norway
Prior art keywords
pharmaceutical agents
modulating
compounds
azepinoindole derivatives
methods
Prior art date
Application number
NO20063080A
Other languages
English (en)
Norwegian (no)
Inventor
Raju Mohan
Richard Martin
Tie-Lin Wang
Brenton Flatt
Xiao-Hui Gu
Brett Busch
Jason H Wu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34679499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063080(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of NO20063080L publication Critical patent/NO20063080L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20063080A 2003-12-02 2006-07-03 Azepinoindolderivater som farmasoytiske midler NO20063080L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/895,431 US7595311B2 (en) 2002-05-24 2003-12-02 Azepinoindole derivatives as pharmaceutical agents
PCT/US2004/040352 WO2005056554A2 (en) 2003-12-02 2004-12-01 Azepinoindole derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
NO20063080L true NO20063080L (no) 2006-08-23

Family

ID=34679499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063080A NO20063080L (no) 2003-12-02 2006-07-03 Azepinoindolderivater som farmasoytiske midler

Country Status (16)

Country Link
US (2) US7595311B2 (pt)
EP (1) EP1692136A2 (pt)
JP (2) JP2007513168A (pt)
KR (2) KR20120091269A (pt)
CN (2) CN1914207A (pt)
AU (1) AU2004297198B2 (pt)
BR (1) BRPI0417260A (pt)
CA (1) CA2555279C (pt)
CR (1) CR8497A (pt)
IL (1) IL176014A0 (pt)
NO (1) NO20063080L (pt)
NZ (1) NZ548179A (pt)
RU (1) RU2423363C2 (pt)
UA (1) UA86957C2 (pt)
WO (1) WO2005056554A2 (pt)
ZA (1) ZA200604352B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US8466143B2 (en) * 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
US7943576B2 (en) * 2005-11-30 2011-05-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of using enterostatin as inhibitor of angiogenesis
EP1963331A1 (en) * 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
MX2009002019A (es) * 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
CA2662574A1 (en) * 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
WO2008074835A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
ATE537143T1 (de) 2008-03-27 2011-12-15 Gruenenthal Gmbh Spiro(5.5)undecan derivate
PT2260042E (pt) * 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos
WO2009118174A1 (de) * 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte cyclohexyldiamine
CA2719735A1 (en) 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
JP5599774B2 (ja) * 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ヒドロキシメチルシクロヘキシルアミン類
CA2736880A1 (en) * 2008-09-26 2010-04-01 Wyeth Llc 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US20110103564A1 (en) * 2009-10-30 2011-05-05 Mitel Networks Corporation System and method for communicating guest preferences to a telephony device
WO2011103487A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103433A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
JP6556129B2 (ja) 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
CN111662297A (zh) * 2014-11-21 2020-09-15 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
WO2016103898A1 (ja) * 2014-12-26 2016-06-30 富士フイルム株式会社 農業ハウス用フィルムおよび農業ハウス
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
EP3715348A1 (en) 2015-03-26 2020-09-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2874632T3 (es) 2016-12-12 2021-11-05 Union Therapeutics As Pirazoloazepin-8-onas sustituidas y su uso como inhibidores de la fosfodiesterasa
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CA3240578A1 (en) * 2021-12-10 2023-06-15 GATC Health Corp Methods of treating ptsd and neurological disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445509A (de) * 1964-12-03 1967-10-31 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
US3839357A (en) * 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
GR35044B (el) 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
FR2455039A1 (fr) 1979-04-26 1980-11-21 Synthelabo Pyrimido et imidazo-pyrido-indole-diones et leur application en therapeutique
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
LU85894A1 (fr) * 1985-05-10 1986-12-05 Omnichem Sa Derives de 1,2,3,4,5,6-hexahydro-azepino (4,5-b) indole leur preparation,composes intermediaires,et leur application en therapeutique
HU198012B (en) 1987-07-03 1989-07-28 Richter Gedeon Vegyeszet Process for producing cyclic amino-acid derivatives and pharmaceutical compositions containing them
BR9709230A (pt) 1996-05-10 1999-08-10 Icos Corp Composto
HUP0302962A2 (hu) 1998-06-12 2003-12-29 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6544984B1 (en) * 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002024700A2 (en) * 2000-09-20 2002-03-28 Pharmacia & Upjohn Company SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US8466143B2 (en) * 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
WO2005056554A3 (en) 2005-08-18
RU2006123424A (ru) 2008-01-10
BRPI0417260A (pt) 2007-03-06
AU2004297198A1 (en) 2005-06-23
WO2005056554A2 (en) 2005-06-23
CA2555279A1 (en) 2005-06-23
JP2011207907A (ja) 2011-10-20
CN1914207A (zh) 2007-02-14
KR20060124662A (ko) 2006-12-05
EP1692136A2 (en) 2006-08-23
US20100173824A1 (en) 2010-07-08
ZA200604352B (en) 2008-12-31
IL176014A0 (en) 2006-10-05
NZ548179A (en) 2009-11-27
CA2555279C (en) 2012-10-23
CR8497A (es) 2006-11-17
RU2423363C2 (ru) 2011-07-10
KR20120091269A (ko) 2012-08-17
US20050054634A1 (en) 2005-03-10
AU2004297198B2 (en) 2012-02-09
US8524704B2 (en) 2013-09-03
JP2007513168A (ja) 2007-05-24
UA86957C2 (ru) 2009-06-10
KR101270072B1 (ko) 2013-05-31
US7595311B2 (en) 2009-09-29
CN102358741A (zh) 2012-02-22

Similar Documents

Publication Publication Date Title
NO20063080L (no) Azepinoindolderivater som farmasoytiske midler
DE60208568D1 (de) Prostaglandinanaloga als ep4-rezeptoragonisten
NO20044826L (no) Pyrrolidinderivater
HRP20080052T3 (hr) Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20050164L (no) Nye quinuklidin-amid-derivater
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
NO20055977L (no) Nye benzimidazolderivater
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
NO970349L (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer
NO984878L (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20070173L (no) Nye forbindelser
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
DE69401584D1 (de) Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application